EU IVDR PSUR under Article 81: Annual Safety Reporting for Class C and D Devices
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Manufacturers of Class C and Class D devices must prepare a Periodic Safety Update Report (PSUR) for each device and, where appropriate, for each category or group of devices. The PSUR summarises the results and conclusions of the analyses of the data gathered under the Article 79 post-market surveillance plan, together with a justification and description of preventive and corrective actions taken, and it must be updated at least annually (Article 81(1)). For Class D devices, the PSUR must be submitted to the notified body involved in the conformity assessment through the electronic system referred to in Article 87, which reviews the report and enters its assessment into that system (Article 81(2)). For Class C devices, the PSUR is made available to the notified body and, upon request, to competent authorities (Article 81(3)). The PSUR cycle therefore rewards manufacturers who treat periodic reporting as a standing process with fixed owners and calendars, rather than as an annual document scramble.
2. Legal basis
| Regulation / document | Provision | Dates | Source |
|---|---|---|---|
| Regulation (EU) 2017/746 (IVDR) | Article 81(1)–(4): (1) PSUR for Class C and D devices and at least annual updates; (2) submission by Class D manufacturers to the notified body via the Article 87 electronic system for review; (3) availability for Class C devices to the notified body and, upon request, to competent authorities | Adopted 2017-04-05; applicable 2022-05-26 | EUR-Lex |
| Same regulation | Article 79 (PMS plan); Article 80 (PMS Report for Class A and B devices); Article 87 (electronic system for vigilance and post-market surveillance); Annexes II and III (the PSUR forms part of the technical documentation) | 2017-04-05 | EUR-Lex |
| Same regulation | Article 113(3)(f) (application arrangements for Article 81(2) before EUDAMED reaches functional status) | 2017-04-05 | EUR-Lex |
3. Expert insights
Insight 1: Of the three mandatory contents of the PSUR, the third is the one most often diluted.
Article 81(1) requires the PSUR to set out, throughout the lifetime of the device: (a) the benefit-risk determination; (b) the main findings of post-market performance follow-up (PMPF); and (c) the sales volume of the device and an estimate of the size and other characteristics of the population using the device, and, where practicable, the usage frequency of the device. Element (c) is decisive because the sales and population data form the denominator of the benefit-risk determination. Without a defensible denominator, the conclusions in (a) cannot be substantiated: a stable complaint count against a growing or shrinking installed base tells a very different story. Yet this is the section most frequently filled with placeholder text. A credible practice is to reconcile sales figures with distribution records at each cycle and to state the estimation method used for the user population, so that the denominator evolves with the market rather than being copied forward.
Insight 2: Class C and Class D face different submission intensity.
Article 81(2) establishes for Class D devices a closed loop of submission, notified body review, and entry of the assessment into the electronic system, with the PSUR and the notified body’s assessment made available to competent authorities through that system. Article 81(3), by contrast, requires only that the manufacturer makes the PSUR available to the notified body and provides it to competent authorities upon request. Class D manufacturers therefore carry an additional review cycle and the potential for resulting corrective obligations, which must be planned into the annual reporting calendar rather than discovered after submission. Where the notified body’s assessment identifies deficiencies, the resulting actions should be tracked to closure under the CAPA system, with the resolution reflected in the next PSUR.
Insight 3: The PSUR is technical documentation and must not be merged with the PMS Report.
The second subparagraph of Article 81(1) states expressly that the PSUR forms part of the technical documentation referred to in Annexes II and III. Class A and Class B devices follow the Article 80 PMS Report route instead: that report is updated when necessary and made available upon request. The two documents differ in scope, in content structure and in update rhythm, and there is no legal basis for combining them into a single periodic document. Keeping the templates separate avoids both audit findings and unnecessary restructuring later.
Insight 4: The status of the Article 87 electronic system shapes the Class D submission route.
Article 81(2) depends on the electronic system for vigilance and post-market surveillance referred to in Article 87. Under Article 113(3)(f), obligations connected with EUDAMED are subject to staged application until EUDAMED is fully functional. As of the verification date of this article, the vigilance and post-market surveillance modules have not yet been declared functionally complete (see article No. 40 in this series), so Class D manufacturers should track subsequent Commission notices and confirm the operative submission route with their notified body before each reporting cycle rather than assuming a fixed channel. Building the PSUR data pipeline so that it can feed either channel is a low-cost hedge against the transition.
4. Practical recommendations
- Establish an annual PSUR calendar with named responsible owners for each Class C or Class D device, category or group, so the at least annual rhythm is never breached.
- Build data templates around the three content elements of Article 81(1), and secure hard data for the sales volume and user population estimate under element (c).
- For Class D devices, agree with the notified body on submission format, review feedback timelines and any corrective follow-up deadlines in advance.
- Cross-reference the PSUR with the Performance Evaluation Report and the risk management file, consistent with Article 56(6), so the documents stay mutually consistent.
- Track Commission notices on the functional status of the Article 87 electronic system, and confirm whether the Class D submission route has changed before each submission.
5. Verification checklist
- □ A PSUR has been established per device / category / group (Article 81(1))
- □ The PSUR contains all three elements: (a) benefit-risk conclusion, (b) PMPF findings, (c) sales volume and population estimates
- □ An update rhythm of at least annual frequency has been set
- □ The submission–review–entry process for Class D devices has been agreed with the notified body (Article 81(2))
- □ The availability and on-request provision arrangements for Class C devices are documented (Article 81(3))
- □ Functional notices on the Article 87 electronic system are on the tracking list
Legal information verified as of 29 October 2026.
GRZAN supports IVD manufacturers on the EU market with the full PSUR lifecycle: building Article 81 reporting calendars, assembling sales and population denominator data, coordinating Class D submissions and notified body review follow-up, and integrating PSUR content with PMPF, performance evaluation and vigilance records. For support with periodic safety reporting under the IVDR, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us